This study investigates the safety and effectiveness of an investigational medication for treating Chronic Hepatitis B in children and adolescents. Chronic Hepatitis B is a long-term liver infection caused by the hepatitis B virus, which can lead to liver damage over time.

Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will measure how well the investigational medication works and its safety.

• Who can participate: Eligible participants are children and adolescents aged 6 to 17 years who have been diagnosed with Chronic Hepatitis B. Additional eligibility criteria include stable liver function tests and no history of severe liver disease or other major health conditions.
• Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo. They will take the assigned treatment and attend regular study visits for monitoring.